US Patent No: 4,606,909

Number of patents in Portfolio can not be more than 2000

Pharmaceutical multiple-units formulation

1 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

A pharmaceutical oral controlled release multiple-units formulation in which individual units comprise cross-sectionally substantially homogeneous cores containing particles of a sparingly soluble active substance, the cores being coated with a coating which is substantially resistant to gastric conditions, but which is erodable under the conditions prevailing in the small intestine, in particular an enteric coating which is substantially insoluble at a pH below 7 such as Eudragit.RTM. S (an anionic polymerizate of methacrylic acid and methacrylic acid methyl ester), is prepared by a process comprising comminuting an active substance together with a substance which is readily soluble in intestinal fluids such as an anionic detergent to obtain particles containing the active substance in intimate admixture with the readily soluble substance, combining the resulting particles into cross-sectionally substantially homogeneous cores together with components which accelerate the disintegration of the cores and intestinal fluids such as talc and saccharose, coating the individual cores with an erodable coating, and combining a multiplicity of the coated cores into a capsule or tablet formulation. Such a coating may also be used when the active substance is a substance which exerts an irritating effect on the gastric mucosa and/or is unstable in an acidic environment.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
BENZON PHARMA, A DANISH LIMITED COMPANYDK-2650 HVIDOVRE13

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bechgaard, Helle Hellerup, DK 3 153
Houmoller, Peter Taastrup, DK 1 77

Cited Art

Patent Info (Count) # Cites Year
 
A/S ALFRED BENZON (1)
4,193,985 Multiple-units drug dose 60 1978
 
SANDOZ LTD. (1)
4,291,016 Enteric coated mixture of 4-(2-hydroxy-3-isopropylamino-propoxy) indole and sodium lauryl sulphate 16 1979

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
ADAMAS PHARMACEUTICALS, INC. (6)
8,293,794 Methods and compositions for the treatment of CNS-related conditions 0 2010
8,283,379 Methods and compositions for the treatment of CNS-related conditions 0 2010
8,362,085 Method for administering an NMDA receptor antagonist to a subject 0 2012
8,338,485 Compositions for the treatment of CNS-related conditions 0 2012
8,338,486 Methods for the treatment of CNS-related conditions 0 2012
8,329,752 Composition for administering an NMDA receptor antagonist to a subject 0 2012
 
ELAN PHARMA INTERNATIONAL LIMITED (5)
5,051,262 Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby 55 1986
4,863,742 Controlled absorption pharmaceutical composition 42 1987
4,917,899 Controlled absorption diltiazem formulation 52 1987
4,891,230 Diltiazem formulation 38 1987
5,002,776 Controlled absorption diltiazem formulations 41 1988
 
ALPHARMA PHARMACEUTICALS, LLC (4)
7,815,934 Sequestering subunit and related compositions and methods 1 2003
8,158,156 Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist 0 2007
7,682,633 Pharmaceutical composition 0 2009
7,682,634 Pharmaceutical compositions 0 2009
 
AMERICAN CYANAMID COMPANY (4)
5,262,173 Pulsatile once-a-day delivery systems for minocycline 20 1992
5,283,065 Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form 67 1992
5,300,304 Pulsatile once-a-day delivery systems for minocycline 14 1992
5,348,748 Pulsatile once-a-day delivery systems for minocycline 16 1993
 
MCNEIL-PPC, INC. (4)
5,075,114 Taste masking and sustained release coatings for pharmaceuticals 69 1990
5,460,825 Taste mask coatings for preparing chewable pharmaceutical tablets 8 1993
5,641,536 Tablet coating method 10 1995
5,641,513 Tablet coating method 9 1995
 
PROGENICS PHARMACEUTICALS, INC. (4)
7,674,904 Synthesis of R-N-methylnaltrexone 8 2006
7,563,899 -methylnaltrexone 6 2006
8,003,794 -methylnaltrexone 1 2009
8,343,992 -methylnaltrexone 0 2010
 
ALTUS PHARMACEUTICALS INC. (3)
6,140,475 Controlled dissolution crosslinked protein crystals 17 1997
6,541,606 Stabilized protein crystals formulations containing them and methods of making them 28 1999
7,351,798 Stabilized protein crystals, formulations comprising them and methods of making them 3 2003
 
HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (3)
5,037,658 Direct dry compressible acetaminophen composition 9 1989
5,198,228 Direct dry compressible acetaminophen tablet 8 1991
5,130,140 Method of making direct dry compressible acetaminophen composition 5 1991
 
INNERCAP TECHNOLOGIES, INC. (2)
7,670,612 Multi-phase, multi-compartment capsular delivery apparatus and methods for using same 3 2004
8,361,497 Multi-phase, multi-compartment, capsular delivery apparatus and methods for using the same 0 2010
 
L. PERRIGO COMPANY (2)
5,773,031 Acetaminophen sustained-release formulation 15 1996
6,126,969 Immediate release/sustained release compressed tablets 24 1997
 
PHARMASCIENCES, INC. (2)
4,925,675 Erythromycin microencapsulated granules 28 1988
4,925,674 Amoxicillin microencapsulated granules 11 1988
 
PLAASKEM (PROPRIETARY) LIMITED (2)
5,208,030 Active ingredient dosage device 7 1990
5,922,337 Active ingredient dosage device 0 1996
 
UNIVERSITY OF CHICAGO, THE (2)
6,274,591 Use of methylnaltrexone and related compounds 20 1998
6,559,158 Use of methylnaltrexone and related compounds to treat chronic opioid use side affects 8 2000
 
WYETH (2)
8,247,425 Peripheral opioid receptor antagonists and uses thereof 1 2009
8,420,663 Peripheral opioid receptor antagonists and uses thereof 0 2012
 
YOSHIAKI KAWASHIMA (2)
5,057,323 Hollow granular medicine and its preparation 0 1989
5,087,455 Hollow granular medicine and its preparation 2 1990
 
501 ELAN CORPORATION PLC. (1)
4,826,688 Controlled absorption pharmaceutical formulation 10 1986
 
APTALIS PHARMA CANADA INC. (1)
6,350,468 Double capsule for the administration of active principles in multiple therapies 6 2000
 
BIOSYTES USA, INC. (1)
5,175,003 Dual mechanism controlled release system for drug dosage forms 23 1990
 
BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (1)
7,713,549 Extended release perforated tablet 1 2006
 
CAROLINA MEDICAL PRODUCTS, INC. (1)
4,837,211 Spironolactone composition 1 1987
 
DAIICHI PHARMACEUTICAL CO., LTD. (1)
6,335,036 Granular pharmaceutical preparation of ebselen 1 1996
 
ELAN CORPORATION, PLC (1)
6,110,494 Cisapride mini-tablet formulations 3 1997
 
EURO-CELTIQUE S.A. (1)
4,844,907 Pharmaceutical composition comprising analgesic and anti-inflammatory agent 97 1986
 
GACELL LABORATORIES AB (1)
5,178,868 Dosage form 51 1991
 
INTELLIPHARMACEUTICS CORP. (1)
8,394,409 Controlled extended drug release technology 0 2004
 
KTS KIGNABB THERAPIE-SYSTEME AG (1)
6,635,276 Oral or mucosal preparation containing an active ingredient, with controlled active ingredient release, and its use 2 2001
 
MAYNE PHARMA INTERNATIONAL PTY LTD (1)
5,277,916 Tetracycline dosage form 20 1990
 
MEPHA AG (1)
4,867,987 Pharmaceutical product for the sustained release of ibuprofen 7 1986
 
MERCK & CO., INC. (1)
4,983,400 Controlled release combination of carbidopa/levodopa 19 1989
 
NEUROMOLECULAR, INC. (1)
8,426,472 Method and composition for administering an NMDA receptor antagonist to a subject 0 2011
 
NISSHIN FLOUR MILLING CO., LTD. (1)
5,080,907 Pharmaceutical preparations containing non-steroidal anti-inflammatory agents 5 1990
 
NOVARTIS;CORPORATE INTELLECTUAL PROPERTY (1)
4,798,724 Solid, stable dosage forms with an elastic film coating 28 1986
 
PHARMACIA & UPJOHN (1)
5,804,217 Manufacturing matrices 1 1995
 
PHARMAVENE, INC. (1)
5,326,570 Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine 43 1991
 
PSICOFARMA, S.A. DE C.V. (1)
7,820,200 Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment 0 2004
 
ROHM GMBH CHEMISCHE FABRIK (1)
5,730,999 Dermal therapeutic system made of a meltable poly (meth) acrylate 24 1996
 
SANOFI-AVENTIS (1)
5,185,159 Pharmaceutical composition based on valproic acid and a process for preparing it 11 1991
 
SHIRE LLC (1)
5,912,013 Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine 46 1995
 
SOCIETE CORTIAL, S.A. (1)
4,780,322 Method of producing slow-release pharmaceutical forms 7 1986
 
STERLING DRUG INC. (1)
5,047,258 Aqueous spray-coating process 23 1990
 
TAKEDA PHARMACEUTICAL COMPANY LIMITED (1)
5,855,914 Granules having core and their production 15 1994
 
TEIJIN LIMITED (1)
4,814,176 Sustained release preparation 41 1986
 
WYETH LLC (1)
8,338,446 Peripheral opioid receptor antagonists and uses thereof 0 2008
 
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (1)
4,913,906 Novel controlled release dosage form of valproic acid 25 1986
 
ZYMA SA (1)
4,784,858 Controlled release tablet 58 1986